SWOG S1404: A phase III randomized trial comparing standard of care adjuvant therapy to pembrolizumab in patients with high risk resected melanoma.

被引：13
|
作者：
Grossmann, Kenneth F.
Othus, Megan
Tarhini, Ahmad A.
Patel, Sapna Pradyuman
Moon, James
Sondak, Vernon K.
Kirkwood, John M.
Ribas, Antoni
机构：
[1] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[2] SWOG Stat Ctr, Seattle, WA USA
[3] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[5] Southwest Oncol Grp, Ctr Stat, Seattle, WA USA
[6] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[7] Univ Pittsburgh, Dept Med, Med Ctr, Pittsburgh, PA USA
[8] UCLA Jonsson Comprehens Canc Ctr, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e21032
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21032
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Adaptlate -a randomized, controlled, open-label, phase-iii trial on adjuvant dynamic marker - adjusted personalized therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) high risk, hr+/her2-early breast cancer
    Gluz, Oleg
    Degenhardt, Tom
    Marschner, Norbert
    Christgen, Matthias
    Kreipe, Hans Heinrich
    Nitz, Ulrike
    Kates, Ronald
    Schinkoethe, Timo
    Graeser, Monika
    Wurstlein, Rachel
    Kuemmel, Sherko
    Harbeck, Nadia
    [J]. CANCER RESEARCH, 2021, 81 (04)
  • [42] A phase III randomized trial of adjuvant biochemotherapy (BC) versus interferon-α-2b (IFN) in patients (pts) with high risk for melanoma recurrence.
    Kim, K. B.
    Legha, S. S.
    Gonzalez, R.
    Anderson, C.
    Papadopoulos, N. E.
    Eton, O.
    Plager, C.
    Roe, A.
    Liu, P.
    Bedikian, A. Y.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 453S - 453S
  • [43] Prognostic value of autoantibodies in melanoma stage III patients in the EORTC 18991 phase III randomized trial comparing adjuvant pegylated interferon α2b vs observation
    Bouwhuis, M. G.
    Suciu, S.
    Testori, A.
    Santinami, M.
    Kruit, W. H.
    Punt, C. J.
    Sales, F.
    Patel, P. M.
    Spatz, A.
    Eggermont, A. M. M.
    [J]. EJC SUPPLEMENTS, 2007, 5 (06): : 5 - 6
  • [44] Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer (JASPAC-01 study)
    Uesaka, Katsuhiko
    Fukutomi, Akira
    Boku, Narikazu
    Kanemoto, Hideyuki
    Konishi, Masaru
    Matsumoto, Ippei
    Kaneoka, Yuji
    Shimizu, Yasuhiro
    Nakamori, Shoji
    Sakamoto, Hirohiko
    Morinaga, Soichiro
    Kainuma, Osamu
    Imai, Koji
    Sata, Naohiro
    Hishinuma, Shoichi
    Nakamura, Takayuki
    Kanai, Michio
    Hirano, Satoshi
    Yoshikawa, Yukinobu
    Ohashi, Yasuo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [45] United States Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon-α2b for resected high-risk melanoma.
    Tarhini, Ahmad A.
    Lee, Sandra J.
    Hodi, F. Stephen
    Rao, Uma N. M.
    Cohen, Gary Irvin
    Hamid, Omid
    Hutchins, Laura Fulper
    Sosman, Jeffrey Alan
    Kluger, Harriet M.
    Sondak, Vernon K.
    Koon, Henry B.
    Lawrence, Donald P.
    Kendra, Kari Lynn
    Minor, David R.
    Lee, Carrie B.
    Albertini, Mark R.
    Flaherty, Lawrence E.
    Petrella, Teresa M.
    Kirkwood, John M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [46] A randomized, multicenter phase III trial comparing regimens of doxorubicin plus cyclophosphamide followed by paclitaxel or doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for patients with high risk breast cancer
    Loesch, D
    Greco, FA
    O'Shaughnessy, J
    Asmar, L
    Senzer, NN
    Burris, HA
    Hainsworth, JD
    Vukelja, S
    Sandbach, J
    Holmes, F
    Sedlacek, S
    Lindquist, D
    Pippen, J
    Olivares, J
    Boehm, KA
    Zhan, F
    Robert, N
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S16 - S17
  • [47] A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma
    Weber, JS
    Hua, FL
    Spears, L
    Marty, V
    Kuniyoshi, C
    Celis, E
    [J]. JOURNAL OF IMMUNOTHERAPY, 1999, 22 (05) : 431 - 440
  • [48] Adjuvant immunotherapy for resected esophageal squamous cell carcinoma with high risk of recurrence (AIRES): A multicenter, open-label, randomized, controlled phase III trial
    Kang, X.
    Xu, J.
    Zhang, R.
    Song, Y.
    Wang, Z.
    Zhang, B.
    Chen, X.
    Zheng, Q.
    Li, Y.
    Qin, J.
    Huang, J.
    Li, Y.
    He, J.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S1072 - S1073
  • [49] EORTC 1325-MG/KEYNOTE-054 phase 3 trial of pembrolizumab versus placebo for completely resected high-risk stage III melanoma: pembrolizumab crossover and rechallenge following recurrence
    Atkinson, Victoria
    Eggermont, Alexander M. M.
    Meshcheryakov, Andrey
    Blank, Christian U.
    Mandala, Mario
    Long, Georgina V.
    Barrow, Catherine
    Di Giacomo, Anna Maria
    Fisher, Rosalie
    Sandhu, Shahneen
    Kudchadkar, Ragini
    Ortiz Romero, Pablo Luis
    Svane, Inge Marie
    van Akkooi, Alexander
    Krepler, Clemens
    Ibrahim, Nageatte
    Marreaud, Sandrine
    Kicinski, Michal
    Suciu, Stefan
    Robert, Caroline
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 161 - 161
  • [50] Randomized phase II trial of postoperative adjuvant capecitabine and temozolomide versus observation in high-risk pancreatic neuroendocrine tumors: SWOG S2104
    Soares, Heloisa P.
    Guthrie, Katherine A.
    Ahmad, Syed A.
    Washington, Mary Kay
    Ramnaraign, Brian Hemendra
    Raj, Nitya Prabhakar
    Seigel, Carole
    Bellasea, Shay
    Chiorean, E. Gabriela
    Dasari, Arvind
    Strosberg, Jonathan R.
    Eng, Cathy
    Philip, Philip Agop
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
12345